Related Experiment Video
Updated: Jul 7, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
[Trends in urology]
Matieu Uffer1, Yves Chollet, Céclie Cardinaux
1Service d'urologie, CHUV, Lausanne. Matieu.Uffer@chuv.ch
Abstract:
The systemic treatment of kidney cancers is promising regarding the first results of the inhibiting molecules of the angiogenesis. Projections in research are encouraging for more specific and sensitive markers of the prostate cancer. For this last the intermittent hormonotherapy improves the quality of life of the patients. The overweight control in infertility allows greater chances of giving birth. The morbidity of the kidney percutaneous surgery is decreased by the use of smaller tools. Reduction rate of reobstruction thanks to new manufactoring stents. The botulinic toxin for the hyperactive bladder refunded by the health insurances.
Insights
New treatments show promise for kidney and prostate cancers. Overweight management aids infertility, while minimally invasive surgery and new stents improve kidney procedures. Botulinum toxin is now covered for overactive bladders.
Area of Science:
- Oncology
- Urology
- Reproductive Medicine
Context:
- Advances in systemic cancer therapies, including angiogenesis inhibitors for kidney cancer.
- Development of novel biomarkers for enhanced prostate cancer detection and management.
- Emerging strategies for improving patient quality of life and surgical outcomes in urological conditions.
Purpose:
- To review recent advancements in the systemic treatment of kidney cancer.
- To highlight progress in identifying specific and sensitive markers for prostate cancer.
- To discuss the benefits of intermittent hormone therapy for prostate cancer patients.
- To explore the role of weight management in addressing infertility.
- To evaluate the impact of minimally invasive techniques and new stent technology on kidney surgery.
- To report on the insurance coverage of botulinum toxin for hyperactive bladder.
Summary:
- Systemic treatments targeting angiogenesis show promise for kidney cancer.
- New markers are being developed for more accurate prostate cancer detection.
- Intermittent hormone therapy enhances the quality of life for prostate cancer patients.
- Weight control improves fertility outcomes.
- Minimally invasive kidney surgery with smaller instruments reduces morbidity.
- Novel stents decrease reobstruction rates.
- Botulinum toxin is now a covered treatment for hyperactive bladder.
Impact:
- Potential for improved cancer treatment efficacy and patient outcomes.
- Enhanced diagnostic capabilities for prostate cancer.
- Better quality of life for patients undergoing hormone therapy.
- Increased success rates for infertility treatments.
- Reduced complications and faster recovery times for kidney surgery patients.
- Improved long-term patency rates for stented procedures.
- Wider accessibility to effective treatment for overactive bladder symptoms.
Related Concept Videos
Urodynamic Studies: Uroflowmetry
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management
Anatomy of the Genitourinary System II: Bladder and Urethra
Nursing Assessment of the Genitourinary System I: Health History
